Meet the Expert: Pfizer - Personalising Patient Care: Reflections on the Place of JAK Inhibitors in Rheumatology


Industry room 1
English
Meet the Experts
03 June 2021 15:00 - 15:30

Learning Objectives:

  • To highlight that JAK inhibitors have been EMA-approved for indications in rheumatology including RA and PsA
  • To share personal experiences with JAK inhibitors and discuss where this class of drugs fits in terms of individualised care
  • To discuss the importance of appropriate drug selection for each patient and what to consider when treating patients with a JAK inhibitor, eg:
    • The growing body of evidence including long-term postmarketing data from the cardiovascular-enriched population in the ORAL Surveillance study
    • How such data allows for an informed risk-benefit assessment in deciding which patients may be candidates for a JAK inhibitor

Presentations

Title Time Calendar .ics
Personalising Patient Care: Reflections on the Place of JAK Inhibitors in Rheumatology
03 June 2021 15:00 - 15:20 .ics
Audience Q&A
03 June 2021 15:20 - 15:30 .ics